TRUE PARTNER (08657) has completed the issuance of convertible bonds in the amount of $2.45 million.
TRUE PARTNER (08657) announces that as of the date of this announcement, all conditions for the conversion of the convertible bonds have been fulfilled. The bond subscription agreement was completed on March 27, 2026, and the Company has issued $2.45 million convertible bonds to the subscriber. As of the date of this announcement, the subscriber has not given notice to the Company for any conversion of the convertible shares.
TRUE PARTNER (08657) announces that as of the date of this announcement, all the conditions precedent for the convertible bonds have been fulfilled. The subscription agreement for the bonds was completed on March 27, 2026, and the company has issued convertible bonds in the amount of $2.45 million to the subscribers. As of the date of this announcement, the subscribers have not issued any conversion notice to convert any of the convertible bonds into shares.
As stated in the letter of consent for cleaning, executive directors Mr. Godefriedus Jelte Heijboer and Mr. Roy van Bakel, as well as independent non-executive directors Mr. Jeronimus Mattheus Tielman and Ms. Bai Wanting (resigned director), have submitted resignation letters to the board on the completion date of the convertible bonds, resigning as executive directors or independent non-executive directors (as the case may be), effective from March 27, 2026.
After March 27, 2026, and the completion of the subscription agreement for the bonds, Mr. Chen Henghui was appointed as the chairman, executive director, and chief business development officer of the company, Mr. Lv Weiliang and Mr. Lin Shenghong were appointed as executive directors, and Mr. Hu Weiliang and Ms. Huang Xiaobin were appointed as independent non-executive directors, all with immediate effect.
Related Articles

INSILICO (03696) reached global pipeline authorization and AI drug development cooperation with Roche.

CMGE(00302) releases annual performance, with a loss of 1.477 billion yuan, a year-on-year decrease of 30.02%.

JIANGSU EXPRESS (00177) has announced its performance for 2025, with a net profit attributable to shareholders of approximately RMB 4.594 billion, representing a year-on-year decrease of about 7.13%.
INSILICO (03696) reached global pipeline authorization and AI drug development cooperation with Roche.

CMGE(00302) releases annual performance, with a loss of 1.477 billion yuan, a year-on-year decrease of 30.02%.

JIANGSU EXPRESS (00177) has announced its performance for 2025, with a net profit attributable to shareholders of approximately RMB 4.594 billion, representing a year-on-year decrease of about 7.13%.

RECOMMEND

Chinese Innovative Drug Assets Attract Major Foreign Acquisition, Cooperation Models Diversify
26/03/2026

Four Giants Subscribe As Memory Manufacturer Confirms TWD 78.718 Billion Private Placement For Capacity Expansion
26/03/2026

Year‑On‑Year Surge Exceeding 500%: Hong Kong IPOs Top HKD 100 Billion This Year
26/03/2026


